The Pentagon, concerned about the threat of germ and
gas warfare, has intensified efforts to bolster US defenses overseas
and at home. For example, DoD ordered 1.4 million active troops
and one million reservists and civilians to be vaccinated against
anthrax, a lethal biological agent. Secretary of Defense William
S. Cohen said the US is studying ways to address special weapons
use in the US itself. In Cohen's view, such arms pose "the
greatest threat that any of us will face in the coming years."
There are numerous weapons of mass destruction--those that
can wipe out military units or populations. What follows is a
look at what American troops and civilians could be facing. The
list is not exhaustive.
|
Who Has
What |
| |
|
|
| Nation |
Biological
Weapons |
Chemical
Weapons |
| China |
Possesses infrastructure
necessary for biowar program. Likely has maintained an offensive
biowar program. |
Produces and is
capable of using wide variety of agents. |
| India |
Has R&D facilities
geared toward biowar defense. |
Has a sizable chemical
industry and recently declared details of its chemwar program. |
| Iran |
Possesses expertise
and infrastructure to support biowar program. May have small
quantities of agents; seeking larger capability. |
Employed chemical
agents on limited scale during IranIraq War. Produces chemical
agents and is capable of use on limited scale. Seeking independent
capability. |
| Iraq |
May retain elements
of its old [preGulf War] program, including some agents
in missile warheads. Could restart some limited agent production
quickly. |
Probably has hidden
precursor chemicals, agents, munitions, documentation for future
effort. Could restart production and have small usable stockpile
in several months. |
| Libya |
Lacks scientific
and technical base. Remains in R&D stage. |
Employed chemical
agents against Chadian troops in 1987; produced blister and nerve
agents in 1980s; is building underground production facility. |
| N. Korea |
Pursued biowar
R&D for many years.
Possesses biotechnical infrastructure capable of supporting limited
biowar effort. |
Produces and is
capable of using wide variety of agents. |
| Pakistan |
May have the capability
to support a limited biowar program. |
Has ability to
transition from R&D to chemical agent production. |
| Syria |
Possesses adequate
biotechnical infrastructure to support biowar program. May be
conducting research related to biowar. |
Produces and is
capable of using chemical agents. Seeking independent chemwar
capability. |
Information on these pages is drawn from "Proliferation:
Threat and Response," Department of Defense; "Biological
Agent Information Papers" and "Medical Management of
Biological Casualties Handbook," US Army Medical Research
Institute of Infectious Diseases, Ft. Detrick, Md.; and "Medical
Management of Chemical Casualties Handbook," US Army Medical
Research Institute of Chemical Defense, Aberdeen Proving Ground,
Md.
Anthrax
Description: Lethal disease caused by infection
with the bacterium Bacillus anthracis. In nature, organisms usually
enter the body through skin wounds but they may be inhaled or
ingested. Intentional release by belligerents or terrorist groups
would presumably involve aerosol means.
Symptoms: The incubation period for inhaled
anthrax is one to six days. Fever, malaise, fatigue, cough, and
chest discomfort are rapidly followed by severe respiratory distress.
Shock and death occur within 24 to 36 hours of the onset of severe
symptoms. In cases of cutaneous anthrax, a papule develops, then
vesicates, finally developing into a black patch surrounded by
moderate to severe edema. Without treatment, this disease may
progress to blood poisoning and death, with a case-fatality rate
of 20 percent. With treatment, fatalities are rare.
Treatment: Penicillin, ciprofloxacin, or
doxycycline, though they are usually ineffective against inhaled
anthrax once symptoms appear.
Protection: A licensed vaccine is available
for use in those at risk of exposure.
Brucellosis
Description: An infection caused by any of four
species of coccobacilli of the genus Brucella. One is normally
a pathogen of cattle, while the other three are pathogens of
goats, pigs, and dogs. Organisms are acquired by humans through
the ingestion of unpasteurized milk and cheese, inhalation of
aerosols generated on farms and in slaughterhouses, or skin lesions
on persons with animal contact. Intentional exposure by belligerents
would likely involve aerosolization but could involve contamination
of food.
Symptoms: Symptoms of brucellosis are nonspecific
and consist of irregular fever, headache, profound weakness and
fatigue, chills and sweating, and generalized arthralgias and
myalgias. Depression and mental status changes are noteworthy.
Osteoarthritic complications, particularly involving the axial
skeleton, are common. Fatalities are uncommon, even in the absence
of therapy.
Treatment: Antibiotics.
Protection: No human brucellosis vaccine
is available.
Cholera
Description: An incapacitating infection caused
by the bacterium Vibrio cholerae, acquired by ingestion of contaminated
water or food. The disease manifests itself as a watery diarrhea
so profuse that supplies of IV fluids are often exhausted during
epidemics. Intentional use by belligerents or terrorist groups
would presumably involve contamination of food or water sources.
Cholera is not itself lethal, but with heavy casualties and the
breakdown in medical care often found in wartime, a large number
of deaths is possible.
Symptoms: Incubation takes one to five days.
While a large number of infected persons remain asymptomatic,
the "classic" form of cholera is noteworthy for its
severity and sudden onset. Vomiting, abdominal distention, and
pain with little or no fever are followed rapidly by a profuse,
watery diarrhea. Fluid losses may readily exceed 10 liters per
day. Without treatment, death may result from severe dehydration
and shock.
Treatment: Fluid and electrolyte replacement
to prevent or overcome severe dehydration. Antibiotics.
Protection: A licensed vaccine is available
but is only modestly effective, providing about 50 percent protection
for six months.
Plague
Description: A lethal infectious disease caused
by the bacterium Yersinia pestis. Naturally occurring plague
is acquired by bite of a flea that has previously fed on infected
rodents. Plague may also be transmitted via aerosol. In such
instances, a pneumonic form may develop and, in the absence of
prompt therapy, progress rapidly to death within three days.
Intentional release by belligerents or terrorists would presumably
involve aerosols.
Symptoms: Pneumonic plague begins with high
fever, chills, headache, and vomiting blood, progressing rapidly
to difficulty breathing and lack of oxygen. Death results from
respiratory failure, circulatory collapse, and bleeding. Bubonic
plague has an incubation period of two to 10 days and causes
malaise, high fever, and tender lymph nodes. Bubonic plague may
progress spontaneously to the septic form, with spread to the
central nervous system and lungs.
Treatment: Antibiotics must be started within
24 hours of onset of symptoms.
Protection: A licensed vaccine is available
but appears to offer little protection against aerosol exposure.
Tularemia
Description: An infection caused by the bacillus
Francisella tularensis. Naturally acquired tularemia is contracted
through bites of certain insects (notably ticks and deerflies)
or contact with infected rabbits, muskrats, and squirrels. Intentional
release by belligerents would presumably involve aerosolization
of living organisms. Naturally acquired tularemia has a fatality
rate of five percent; the pneumonic form, which would predominate
in war, would likely have a greater mortality rate.
Symptoms: Incubation averages three to five
days. Use of tularemia as a weapon would likely lead to preponderance
of pneumonic and typhoidal cases, and large aerosolized attacks
would be expected to shorten the incubation period. Victims would
have tender ulcers at the site of inoculation, accompanied by
tender, enlarged regional lymph nodes. Fever, chills, headache,
and malaise often accompany these symptoms. Typhoidal and pneumonic
forms often involve significant cough, abdominal pain, substernal
discomfort, and prostration, in addition to fever, chills, and
headache.
Treatment: Antibiotics, though relapses may
occur.
Protection: A live, attenuated vaccine is
available as an investigational product. Intramuscular streptomycin
will prevent disease following documented exposure.
Q Fever
Description: An infection with the rickettsial
organism Coxiella burnetii, typically spread by inadvertent aerosolization
of organisms from infected animal products. Person-to-person
transmission rarely occurs. Intentional release by belligerents
or terrorist groups would presumably involve aerosolization,
and Q fever would likely be employed as an incapacitating agent,
as its mortality rate is low, only one to three percent.
Symptoms: Q fever typically starts as an
undifferentiated illness with fever, chills, cough, headache,
weakness, and chest pain occurring as early as 10 days after
exposure. Onset may be sudden or insidious. Pneumonia is present
in some cases, but pulmonary syndromes are usually not prominent.
The illness lasts from two days to two weeks.
Treatment: Antibiotics. Q fever is generally
a self-limited illness even without treatment.
Protection: Treatment with tetracycline or
doxycycline within 12 days of exposure should prevent onset of
symptoms. Vaccine is available as an investigational agent.
Smallpox
Description: A lethal infection caused by the
variola virus, a member of the Chordopoxvirus family. Naturally
occurring smallpox has been eradicated from the globe, with the
last known case occurring in Somalia in 1977. Repositories of
virus are known to exist in only two laboratories. Monkeypox,
cowpox, and vaccinia are closely related viruses, however, which
might lend themselves to genetic manipulation and the subsequent
production of smallpox-like disease.
Symptoms: The incubation period of smallpox
is about 12 days. Clinical manifestations begin acutely with
a period involving malaise, fevers, rigors, vomiting, headache,
and backache. After two to four days, skin lesions appear and
begin to progress uniformly from macules to papules to vesicles
and pustules. Lesions progress centrifugally and scab in one
to two weeks. In unvaccinated individuals, variola major, the
classical form of the disease, is fatal in some 30 percent of
cases.
Treatment: Supportive care is the mainstay
of smallpox therapy. No specific antiviral therapy exists.
Protection: A licensed, live vaccinia virus
vaccine is available and is administered via a bifurcated needle
using a multiple puncture technique. Vaccine would only be indicated
in laboratory settings or where biological warfare was a distinct
possibility.
Venezuelan Equine Encephalitis
Description: A mosquito-borne disease maintained
in a horsemosquitohorse cycle, though thousands of human infections
also occur each year. Large outbreaks among horses typically
precede appearance of human cases. Use of VEE as a weapon would
presumably involve aerosolization.
Symptoms: VEE is an incapacitating agent
with a mortality rate of less than one percent. Susceptibility
is nearly 100 percent, however. The disease is characterized
by sudden onset following a one-to-five-day incubation. Initial
symptoms include malaise, severe headache, fever and rigors,
photophobia, and myalgias. Cough, sore throat, and vomiting and
diarrhea may follow. Only a small percentage of cases actually
progress to encephalitis, which is more frequent in young children
and is marked by convulsions, coma, and paralysis. In a majority
of cases without neurologic complications, however, full recovery
occurs in one to two weeks.
Treatment: Largely supportive.
Protection: Vaccine TC-83 is available as
investigational product.
Viral Hemorrhagic Fevers
Description: A diverse group of human illnesses
caused by viruses from several different families: the Filoviridae,
which consists of Ebola and Marburg viruses; the Arenaviridae,
including Lassa fever, Argentine, and Bolivian hemorrhagic fever
viruses; the Bunyaviridae, including various members from the
Hantavirus genus, CongoCrimean hemorrhagic fever virus from the
Nairovirus genus, and Rift Valley fever from the Phlebovirus
genus; and Flaviviridae, such as yellow fever virus, dengue hemorrhagic
fever virus, and others.
Symptoms: VHFs are illnesses which can be
complicated by easy bleeding, petechiae, hypotension and even
shock, flushing of the face and chest, and edema. Constitutional
symptoms such as malaise, myalgias, headache, vomiting, and diarrhea
may occur.
Treatment: Antiviral therapy with ribavirin
may be useful in several of these infections.
Protection: The only licensed VHF vaccine
is yellow fever vaccine. Prophylactic ribavirin may be effective
for Lassa fever, Rift Valley fever, CCHF, and possibly hemorrhagic
fever with renal syndrome.
Botulism
Description: Lethal illness caused by any of
seven related neurotoxins produced by the bacterium Clostridium
botulinum. They are typically formed in canned foods and subsequently
ingested, although the spore form may occasionally gain access
to the body through wounds or gastrointestinal tract. Intentional
release by belligerents or terrorists would likely involve aerosolization
of preformed toxins, which then produce disease via inhalation.
Symptoms: Drooping eyelids, generalized weakness,
dizziness, dry mouth and throat, blurred vision, slurred speech,
and difficulty in swallowing are followed by symmetrical descending
paralysis and the development of respiratory failure. Symptoms
may begin as early as 12 to 36 hours following ingestion or inhalation
but could take as long as several days.
Treatment: Supportive care is the mainstay
of therapy. For respiratory failure, tracheostomy may be required.
A licensed trivalent equine botulinum antitoxin is available.
Protection: Toxoid available as an investigational
product.
Staphylococcal Enterotoxin B Disease
Description: An incapacitating illness caused
by SEB, one of several toxins produced by the bacterium Staphylococcus
aureus. SEB is a common contributor to food poisoning but could
be employed by belligerents or terrorist groups as an aerosolized
inhalational agent. It is incapacitating but rarely lethal.
Symptoms: Symptoms appear three to 12 hours
after aerosol exposure and consist of sudden onset of fever,
chills, headache, myalgia, and cough. Some patients may develop
shortness of breath and retrosternal chest pain. Fever may last
two to five days, and cough may persist for four weeks. Patients
ingesting toxin might suffer nausea, vomiting, and diarrhea.
Very high exposure levels may lead to pulmonary edema and, though
rare, death.
Treatment: Treatment is limited to supportive
care. No antitoxin has been developed.
Protection: Currently no human vaccine is
available to prevent SEB intoxication.
Ricin Intoxication
Description: A lethal illness caused by ricin,
a protein toxin which acts as a cellular poison. Ricin is readily
produced from castor beans, ubiquitous throughout the world.
Five percent of all waste from commercial production of castor
oil is ricin. Natural cases of ricin intoxication involve ingestion
of castor beans, which causes severe GI symptoms, vascular collapse,
and death. Ricin use by belligerents might involve the poisoning
of water or foodstuffs, use of ricin-laced projectiles, or aerosolization
of ricin as a liquid or freeze-dried powder.
Symptoms: When inhaled as an aerosol, ricin
would likely cause symptoms within eight hours. Fever, cough,
difficulty breathing, nausea, and chest tightness are followed
by profuse sweating, development of pulmonary edema, cyanosis,
hypotension, and finally respiratory failure and circulatory
collapse. Death would occur in 36 to 72 hours, depending on size
of the dose.
Treatment: No specific antitoxin treatment
exists.
Protection: A protective mask offers protection
from aerosol exposure, but no specific vaccine exists.
Trichothecene Mycotoxicosis
Description: Disease caused by the trichothecene
mycotoxins, poisons produced by several species of fungi. Most
are potent inhibitors of protein synthesis and respiration. The
toxins most frequently isolated from agricultural products, and
likewise mentioned most often in the context of belligerent use,
include diacetoxyscirpenol (DAS), Nivalenol, 4-Deoxynivalenol
(DON), and especially T-2. T-2, one of the most stable types,
is perhaps the most likely to be employed in terrorism or warfare.
Intentional use of T-2 by belligerents might involve aerosolization
or contamination of food.
Symptoms: Skin exposure leads to symptoms
within minutes, including redness of the skin, pain, and a burning
sensation. Blisters form and progress to necrosis with a leathery
blackening of the skin. Inhalational exposure produces a rapid
onset of nose and throat pain, with nasal discharge, cough, labored
breathing, wheezing, chest pain, and coughing up of blood. Eyes
are likewise affected with intense burning. GI exposure leads
to loss of appetite, nausea, abdominal cramping, and watery or
bloody diarrhea.
Treatment: Standard poison management techniques,
such as the use of superactivated charcoal, are useful when administered
early to casualties with gastrointestinal exposure.
Protection: Physical means, such as a protective
mask and clothing.
Tabun (GA), Sarin (GB), Soman (GD),
GF, VX
Description: The most toxic of the known chemical
agents. Nerve agents are extreme hazards in their liquid and
vapor states and can cause death minutes after exposure. Nerve
agents inhibit certain enzymes in tissue; effects are caused
by resulting excess compounds. Nerve agents are considered major
military threats. They can be dispersed from missiles, rockets,
bombs, howitzer shells, spray tanks, land mines, and other large
munitions.
Symptoms: Small exposure to vapor brings
constriction of the pupils, nasal inflammation, and mild difficulty
breathing, while a large exposure to vapor causes sudden loss
of consciousness, convulsions, a halt in breathing, paralysis,
and death. Small to moderate exposure of liquid on skin produces
localized sweating, nausea, vomiting, and a feeling of weakness,
while a large exposure to liquid on skin has same effect as vapor
exposure. Lethal amounts of vapor or liquid cause a rapid cascade
of events culminating, within a minute or two, with loss of consciousness
and convulsive activity followed by a halt in breathing within
several more minutes.
Treatment: Three drugs--atropine, pralidoxime
chloride, and diazepam--are used to treat nerve agent exposure.
Protection: Pyridostigmine bromide as a pretreatment.
Protective masks, clothing.
Mustard (H, HD)
Description: A major military threat agent since its
introduction in World War I, mustard is an oily liquid with color
ranging from a light yellow to brown and has an odor of garlic,
onion, or mustard (hence its name). Mustard constitutes both
a vapor and a liquid threat to exposed skin and mucous membranes.
Effects are delayed, appearing hours after exposure. A vesicant,
it causes vesicles (blisters) on the skin; however, these agents
also damage the eyes and airways by direct contact and have other
effects.
Symptoms: Blisters on the skin; irritation,
conjunctivitis, corneal opacity, and damage in the eyes; mild
upper respiratory irritation and burning progresses to marked
airway damage; also nausea and vomiting and bone marrow damage.
Organs most commonly affected are skin, eyes (with mild conjunctivitis
to severe eye damage), and airways (with mild irritation of the
upper respiratory tract to severe bronchiolar damage leading
to necrosis and hemorrhage of the airway). The GI tract may be
damaged. Death stems from respiratory failure, bacterial pneumonia,
or immune system failure.
Treatment: No specific antidote. Immediate
decontamination is the only way to reduce damage.
Protection: Protective mask, clothing.
Lewisite (L)
Description: An oily, colorless liquid, having
the odor of geraniums. It is a vesicant that damages eyes, skin,
and airways by direct contact. After absorption, it causes an
increase in capillary permeability to produce shock and organ
damage.
Symptoms: Lewisite causes immediate pain
or irritation of skin and mucous membranes. Blisters on the skin,
and eye and airway damage similar to those seen after mustard
exposure, develop later. A person with a droplet of Lewisite
on his skin will note the burning and will immediately take steps
to try to remove it. The vapor is so irritating that a person
will seek to leave a contaminated area. Because this warning
causes the person exposed to take immediate steps to decontaminate,
the Lewisite lesion will probably not be as severe as a mustard
lesion.
Treatment: Immediate decontamination and
treatment of lesions. A specific antidote, BritishAnti-Lewisite,
decreases systemic effects but causes some toxicity itself.
Protection: Protective mask, clothing.
Phosgene Oxime (CX)
Description: Phosgene oxime is an itchingstinging
agent that causes a corrosive skin and tissue lesion. The vapor
is extremely irritating, and both vapor and liquid cause almost
immediate tissue damage. The mechanism by which phosgene oxime
causes biological effects is unknown.
Symptoms: On the skin and all mucous membranes,
CX liquid or vapor causes immediate pain on contact. Extreme
pain may persist for days. It is irritating and painful to the
eyes and upper airways. Agent causes pulmonary edema after inhalation
and after skin contact. Some data suggest that CX may cause hemorrhagic
inflammatory changes in the GI tract.
Treatment: Immediate decontamination.
Protection: Protective mask, clothing.
Hydrocyanic Acid (AC), Cyanogen
Chloride (CK)
Description: A rapidly acting lethal agent that
is limited in its military usefulness by its high volatility.
However, at high concentrations, cyanide kills quickly. Cyanides
are sometimes called "blood agents." Cyanides are in
liquid state in munitions but rapidly vaporize upon detonation
of the munitions.
Symptoms: After exposure to heavy dose, seizures,
respiratory failure, and cardiac arrest appear. The organs most
susceptible to cyanide are the central nervous system and the
heart. Most clinical effects are of CNS origin and are nonspecific.
About 15 seconds after inhalation of concentrated vapor, there
is abnormally deep breathing followed in 15 to 30 seconds by
convulsions. Respiratory activity stops two to three minutes
later, and cardiac activity ceases several minutes later still
or at about six to eight minutes after exposure.
Treatment: Sodium nitrite and sodium thiosulfate
are effective antidotes. Amyl nitrite also is useful.
Protection: Protective mask, clothing.
Phosgene, Others
Description: A lung-damaging liquid dispersed
in a liquid-filled shell that explodes, rapidly vaporizing as
a low-lying, white cloud of gas. It has a characteristic odor
of sweet, newly mown hay or freshly cut grass or corn.
Symptoms: After a latent period, the victim
experiences worsening respiratory distress that at first is unaccompanied
by signs of pulmonary damage but that may progress relentlessly
to death. Irritation of the larynx by very large concentrations
of the agent may lead to sudden laryngeal spasm and death. The
most prominent symptom following the latent period is difficulty
breathing, perceived as shortness of breath with or without chest
tightness. Death results from respiratory failure or in combination
with the effects of lack of oxygen to vital organs and tissues.
Complications include infection of damaged lungs and delayed
death following such respiratory infections.
Treatment: No antidote.
Protection: Protective mask, clothing.
Copyright Air Force Association. All rights reserved
|